Scientific deep-dive

Foundayo (Orforglipron) Side Effects: Comprehensive Evidence Review

Comprehensive Foundayo (orforglipron) adverse-event review across the three pivotal trials: ATTAIN-1 in obesity, ATTAIN-2 in T2D, and ATTAIN-MAINTAIN switch-and-maintain. GI dominance, dose discontinuations, class warnings, and head-to-head AE comparison with Wegovy and Zepbound.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
14 min read·8 citations

Frequently Asked Questions

Across ATTAIN-1, ATTAIN-2, and ATTAIN-MAINTAIN, the most common adverse events are gastrointestinal: nausea, diarrhea, constipation, vomiting, and dyspepsia. Most were mild to moderate and concentrated in the dose-escalation weeks. The pattern matches injectable GLP-1s such as Wegovy and Zepbound.
Yes. The Foundayo FDA label carries the GLP-1 class boxed warning for thyroid C-cell tumors, which observed in rodents at clinically relevant exposures. The boxed warning instructs against use in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.
Uncommonly, and mostly in type 2 diabetes. The label says Foundayo can cause hypoglycemia: glucose below 54 mg/dL was reported in 0.6% of patients without diabetes (vs 0% on placebo), and in 2% vs 0.2% in the type 2 diabetes trial, rising to 7% in patients also taking a sulfonylurea (vs 0.5% without). Insulin also raises the risk, so prescribers may lower the insulin or sulfonylurea dose when starting Foundayo.
No. The FDA label says to take Foundayo once daily, with or without food, and to swallow the tablet whole without breaking, crushing, or chewing it. Unlike Rybelsus and the Wegovy pill, there is no water rule or 30-minute wait: the label reports no clinically relevant food effect on orforglipron exposure.
Across the three pivotal trials, Foundayo's gastrointestinal adverse-event profile is broadly similar to Wegovy (STEP-1) and Zepbound (SURMOUNT-1). Nausea, diarrhea, and constipation rates land in roughly the same range; treatment discontinuation due to adverse events across the ATTAIN-1 orforglipron arms (6 to 36 mg in the trial, sold as 5.5 to 17.2 mg) was 5.3 to 10.3%, comparable to the high-dose injectable arms.
The FDA Foundayo label carries the class warnings for acute pancreatitis and acute gallbladder disease consistent with other GLP-1 receptor agonists. Pivotal-trial event counts were small. As with any GLP-1, persistent severe abdominal pain that may radiate to the back, or right-upper-quadrant pain with fever or jaundice, should be evaluated promptly.
Yes, with caution. The Foundayo FDA label warns of increased hypoglycemia risk when used with insulin or insulin secretagogues such as sulfonylureas. ATTAIN-2 mirrored this pattern. Most guidelines recommend the prescribing clinician reduce the insulin or sulfonylurea dose at Foundayo initiation and monitor glucose closely during titration.
No. The Foundayo FDA label, like the other weight-management GLP-1 labels, advises against use in pregnancy: animal data suggest potential fetal harm, and weight loss is not an obesity-treatment goal during pregnancy. The label directs stopping the drug as soon as a pregnancy is recognized. Pregnancy is not listed among its contraindications, and unlike the semaglutide labels (Wegovy, Ozempic, and Rybelsus), the orforglipron label sets no pre-conception window. Patients of childbearing potential should use effective contraception and talk to their prescriber about timing before trying to conceive.
The label sets no food restriction: Foundayo can be taken with or without food. The foods that most reliably worsen side effects on any GLP-1 apply here: high-fat, greasy, or very rich meals tend to intensify nausea and vomiting, especially during the dose-escalation weeks; very large portions overwhelm a stomach that is already slowed by GLP-1 receptor activation. Carbonated beverages can worsen bloating and distension. There is no specific dangerous food-drug interaction with orforglipron itself, but alcohol should be minimized as it adds empty calories and can amplify GI upset.
Nausea and other GI side effects that tend to appear in the first days to weeks of each new dose step are also a sign of absorption and receptor activation. Meaningful weight loss accumulates more slowly: in ATTAIN-1, significant weight reduction was measured out to 72 weeks, with the top dose (36 mg in the trial, sold as the 17.2 mg tablet) producing an average of -11.2 percent body weight. Patients switching from an injectable GLP-1 via ATTAIN-MAINTAIN saw weight preservation effects from orforglipron within the first weeks of switching. The practical expectation is body-weight changes becoming visible over months as titration continues. The label moves patients up to 5.5 mg, then allows increases to 9, 14.5, or 17.2 mg based on response and tolerability; the maximum is 17.2 mg once daily.

The honest answer:

Foundayo (orforglipron) is a once-daily oral small-molecule GLP-1 receptor agonist, FDA-approved April 1, 2026 for chronic weight management. Across the three phase 3 trials — ATTAIN-1 in adults with obesity without diabetes[1], ATTAIN-2 in adults with obesity and type 2 diabetes[2], and the ATTAIN-MAINTAIN switch-and- maintain trial[3] — the adverse-event profile is dominated by mild-to-moderate gastrointestinal events (nausea, diarrhea, constipation, vomiting, dyspepsia) that concentrate during dose escalation and attenuate thereafter. The Foundayo FDA label carries the GLP-1 class boxed warning for thyroid C-cell tumors and the standard class warnings for acute pancreatitis, acute gallbladder disease, acute kidney injury secondary to volume contraction, and hypoglycemia when combined with insulin or a sulfonylurea[4]. Adverse-event discontinuations across the orforglipron arms ran 5.3 to 10.3% in ATTAIN-1 and 6.1 to 9.9% in ATTAIN-2, comparable to injectable Wegovy and Zepbound. Unlike Rybelsus or the Wegovy pill, Foundayo is taken with or without food and with no 30-minute wait, one of the practical gaps in the Foundayo vs Rybelsus comparison. The trials dosed it as 6, 12, and 36 mg, which the label reports as the marketed 5.5, 9, and 17.2 mg tablets. One label caution: people using oral contraceptives should switch to a non-oral method or add a barrier method for 30 days after starting and after each dose increase.

At a glance

  • Foundayo is the first small-molecule (non-peptide) oral GLP-1 pill approved for chronic weight management. FDA approval was granted April 1, 2026 for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity[4]. Unlike Rybelsus (oral semaglutide), orforglipron is a non-peptide small molecule, which makes oral absorption more reliable but does not change the underlying GLP-1 receptor agonist pharmacology.
  • The pivotal ATTAIN-1 trial randomized 3,127 adults to once-daily orforglipron 6, 12, or 36 mg or placebo for 72 weeks. Mean weight loss at the 36 mg arm was -11.2% on the treatment- regimen estimand[1]. The most common adverse events were gastrointestinal effects, mostly mild to moderate, and adverse events caused treatment discontinuation in 5.3 to 10.3% of patients in the orforglipron groups vs 2.7% on placebo.
  • ATTAIN-2 confirmed the AE profile in a T2D population. Across 1,613 adults with type 2 diabetes (baseline HbA1c 8.05%), Foundayo at 36 mg produced -9.6% weight loss at 72 weeks vs -2.5% placebo, with treatment discontinuations due to adverse events of 6.1 to 9.9% on Foundayo vs 4.1% on placebo — mainly GI-related[2].
  • ATTAIN-MAINTAIN tested switching from injectable GLP-1 to oral Foundayo for maintenance. SURMOUNT-5 completers who had taken tirzepatide (cohort 1, n=205) or semaglutide (cohort 2, n=171) were randomized to oral orforglipron or placebo for 52 weeks. Foundayo preserved 74.7 to 79.3% of the prior body-weight reduction vs 37.6 to 49.2% with placebo, with adverse events again predominantly mild-to-moderate GI[3].
  • The FDA Foundayo label boxed warning is for thyroid C-cell tumors. This is a GLP-1 class label finding observed in rodents at clinically relevant exposures. Foundayo is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2[4].
  • Hypoglycemia is uncommon without diabetes and more likely in T2D combination therapy. The label says Foundayo can cause hypoglycemia. Glucose below 54 mg/dL was reported in 0.6% of patients in the trial without diabetes (vs 0% on placebo) and in 2% vs 0.2% in the type 2 diabetes trial, where it reached 7% in patients also on a sulfonylurea. Insulin raises the risk too, because the GLP-1 effect on insulin secretion stacks with the secretagogue or exogenous insulin[2][4].
  • The dosing instructions are simple. The Foundayo label calls for one tablet a day, with or without food, swallowed whole; there is no water rule or 30-minute wait as with Rybelsus or the Wegovy pill. A missed dose is taken as soon as possible without doubling the next one; after 7 or more missed doses in a row, escalation restarts at a lower dose to reduce the risk of GI adverse events.
  • Pregnancy and certain renal warnings apply. The label warns of possible fetal harm and directs stopping Foundayo as soon as a pregnancy is recognized; effective contraception is advised. Pregnancy is not one of the label’s contraindications, and the label sets no pre-conception window — that wording appears only on the semaglutide labels (Wegovy, Ozempic, and Rybelsus). Acute kidney injury secondary to volume contraction from severe GI losses is labeled, the same class warning as for Wegovy and Zepbound[4].

What ATTAIN-1, ATTAIN-2, and ATTAIN-MAINTAIN actually reported

The Foundayo adverse-event evidence base rests on three phase 3 randomized trials, all published in top-tier journals and all consistently describing the same broad pattern: dominant mild-to-moderate gastrointestinal effects concentrated during dose escalation, with serious adverse events that follow the GLP-1 class pattern rather than introducing any unique signal specific to the oral small-molecule mechanism.

A note on doses, because 36 mg is not sold. The trial papers report an investigational formulation dosed as 6, 12, and 36 mg. The marketed tablets carry different numbers: the FDA label presents these same trial arms as 5.5, 9, and 17.2 mg[4], and a bioequivalence study matched capsule doses of 6, 12, and 36 mg to those tablet doses[8]. So when this article says 36 mg, the pharmacy equivalent is the 17.2 mg tablet, which is the labeled maximum. The label says not to take more than one tablet per day.

ATTAIN-1 (Wharton and colleagues, published in the November 6, 2025 issue of the New England Journal of Medicine)[1] randomized 3,127 adults with obesity without type 2 diabetes to once-daily oral orforglipron at 6 mg, 12 mg, or 36 mg, or placebo, in a 3:3:3:4 ratio, for 72 weeks as an adjunct to a healthy diet and physical activity. The primary endpoint was percent change in body weight from baseline to week 72, treatment-regimen estimand. The 36 mg arm produced -11.2% mean weight change (95% CI -12.0 to -10.4), the 12 mg arm -8.4%, the 6 mg arm -7.5%, vs -2.1% on placebo. Adverse events caused treatment discontinuation in 5.3 to 10.3% of orforglipron patients (dose-dependent) vs 2.7% on placebo. The most common adverse events were gastrointestinal effects, mostly mild to moderate, and the safety profile was, in the investigators’ own framing, “consistent with that of other GLP-1 receptor agonists.”

ATTAIN-2 (Horn and colleagues, published online November 20, 2025 in The Lancet)[2] was the parallel phase 3 trial in adults with obesity and type 2 diabetes (BMI ≥27, HbA1c 7-10%). Participants were randomized 1:1:1:2 to orforglipron 6 mg, 12 mg, 36 mg, or placebo for 72 weeks. Of 1,613 randomized, 1,444 (89.5%) completed. Baseline body weight was 101.4 kg, BMI 35.6, and HbA1c 8.05%. At the 36 mg arm, mean weight change at 72 weeks was -9.6% (95% CI -10.5 to -8.7), with -7.0% at 12 mg and -5.1% at 6 mg, vs -2.5% on placebo. Treatment discontinuations due to adverse events were higher with orforglipron (6.1 to 9.9%) than with placebo (4.1%), and were again predominantly gastrointestinal. The investigators reported ten deaths during the study (six on orforglipron, four on placebo), all but two adjudicated as unrelated to study treatment.

ATTAIN-MAINTAIN (Aronne and colleagues, published online May 13, 2026 in Nature Medicine)[3] tested a distinct clinical question: can oral Foundayo maintain weight loss achieved on injectable therapy? SURMOUNT-5 completers were enrolled into two cohorts: cohort 1 (n=205) had previously taken tirzepatide; cohort 2 (n=171) had previously taken semaglutide. Participants who had achieved body-weight plateau were randomized to oral orforglipron or placebo for 52 weeks. Cohort 1 preserved a model-based estimate of 74.7% of body-weight reduction with Foundayo vs 49.2% with placebo (estimated treatment difference 25.5%; P<0.001). Cohort 2 preserved 79.3% with Foundayo vs 37.6% with placebo (estimated treatment difference 41.7%; P<0.001). The most common adverse events were — again — mild-to- moderate gastrointestinal effects.

Three independent randomized trials in three distinct populations (no T2D, T2D, post-injectable maintenance) reported the same broad AE pattern. That is the strongest possible evidence that the GI dominance and the absence of any oral-formulation-specific unique adverse event are real characteristics of the molecule, not a quirk of a single trial. For the pivotal weight-loss efficacy reframing alongside this safety review, see our patient-facing Foundayo side effects guide and the Foundayo FDA approval announcement.

What the label says about daily dosing and the AE profile

Foundayo is the first once-daily oral non-peptide GLP-1 RA. Unlike Rybelsus and the Wegovy pill, the FDA label says to take it with or without food, with no water rule or 30-minute wait, and to swallow the tablet whole without breaking, crushing, or chewing it[4]. The food-effect study described in the label found no clinically relevant effect of food on orforglipron exposure.

What does affect tolerability is the pace of escalation. GI adverse events in the trials concentrated in the dose-escalation weeks[2], and the label says to take a missed dose as soon as possible without doubling the next one, and to restart escalation at a lower dose if 7 or more doses in a row are missed, to reduce the risk of GI adverse events[4].

One practical label caution: because Foundayo delays gastric emptying, people using oral hormonal contraceptives should switch to a non-oral method or add a barrier method for 30 days after starting and for 30 days after each dose increase[4]. The Foundayo dosing and administration guide walks through daily dosing in more detail.

Common gastrointestinal adverse events: rates and timing

Across all three ATTAIN trials, the most common adverse events with Foundayo were gastrointestinal: nausea, diarrhea, constipation, vomiting, and dyspepsia (indigestion / upper abdominal discomfort). The events were mostly mild to moderate in severity and concentrated during the dose-escalation period rather than the maintenance period[1][2][3]. The FDA label pools ATTAIN-1 and ATTAIN-2 and reports the trial arms as equivalent doses of the marketed tablets: GI adverse reactions occurred in 60% at the lowest dose (5.5 mg, the trials’ 6 mg), 68% at the middle dose (9 mg, the trials’ 12 mg), and 69% at the top dose (17.2 mg, the trials’ 36 mg), vs 37% on placebo[4]. So the rate rose from the lowest dose to the middle dose and then leveled off.

The clinical implication is the same as for every other GLP-1 receptor agonist: GI tolerability is the dominant tolerability challenge, and it is largely time-limited per dose step rather than persistent across the full treatment duration. Patients who can get through the 2-to-4-week adaptation window at each dose increase typically reach a tolerable steady state at the maintenance dose. Patients who cannot tolerate a particular dose step have the option of staying at the lower dose for an additional cycle, slowing the titration, or in some cases backing off to the previous dose and re-attempting the step after a stability period.

Practical mitigation strategies that work for injectable GLP-1 nausea generally translate: smaller meals, avoiding very rich or greasy foods, eating slowly, stopping at the first sign of fullness, staying hydrated, and (for nighttime nausea) avoiding large evening meals. For a deeper walkthrough of patient questions about GLP-1 GI side effects, see the GLP-1 side effects Q&A and the interactive GLP-1 side-effect timeline tool.

Class-effect warnings: thyroid, pancreatitis, gallbladder

The Foundayo FDA label carries the standard GLP-1 receptor agonist class warnings[4]. Three are clinically load-bearing:

  • Boxed warning — thyroid C-cell tumors. GLP-1 receptor agonists produced thyroid C-cell tumors in rodent studies at clinically relevant exposures. Human relevance is unclear; postmarket surveillance for medullary thyroid carcinoma has not demonstrated a clear signal. The boxed warning instructs against use in patients with a personal or family history of medullary thyroid carcinoma, or patients with Multiple Endocrine Neoplasia syndrome type 2. This is identical to the Wegovy, Ozempic, Zepbound, Mounjaro, and Saxenda labels.
  • Acute pancreatitis (labeled warning). Pancreatitis has been reported across the GLP-1 class. The Foundayo label instructs prompt evaluation if pancreatitis is suspected (severe persistent abdominal pain, possibly radiating to the back) and discontinuation if pancreatitis is confirmed. The pivotal-trial event counts were small. Patients with a history of pancreatitis should discuss benefit-risk explicitly with the prescriber.
  • Acute gallbladder disease (labeled warning). Cholelithiasis and cholecystitis are documented in the GLP-1 class, partly mediated by rapid weight loss itself (a known independent risk factor) and partly by direct effects on gallbladder motility. Right-upper-quadrant pain with fever or jaundice warrants prompt evaluation.

Additional labeled warnings include acute kidney injury secondary to volume contraction from severe GI losses (nausea, vomiting, diarrhea), hypersensitivity reactions (including rare anaphylaxis and angioedema), diabetic retinopathy complications in patients with type 2 diabetes (a class observation rather than a Foundayo-specific finding), and the hypoglycemia warning, with the highest risk when combined with insulin or a sulfonylurea (discussed separately below). The label also warns against use in pregnancy and breastfeeding, directing that the drug be stopped once a pregnancy is recognized.

How Foundayo compares to injectable Wegovy and Zepbound

The clinically relevant comparison is whether Foundayo’s oral once-daily dosing produces a meaningfully different adverse-event profile than the established injectable once-weekly options (Wegovy = semaglutide 2.4 mg sc weekly; Zepbound = tirzepatide up to 15 mg sc weekly). On the head-to-head pivotal-trial data, the answer is mostly no.

STEP-1 (Wilding and colleagues 2021, NEJM)[5] randomized 1,961 adults with obesity to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks. The GI adverse-event rates were dominated by nausea (44.2%), diarrhea (31.5%), vomiting (24.8%), and constipation (23.4%) on semaglutide, vs much lower rates on placebo. Treatment discontinuation due to adverse events was 7.0% on semaglutide vs 3.1% on placebo. Mean weight change was -14.9% at 68 weeks vs -2.4% on placebo.

SURMOUNT-1 (Jastreboff and colleagues 2022, NEJM)[6] randomized 2,539 adults with obesity to once-weekly subcutaneous tirzepatide 5, 10, or 15 mg or placebo for 72 weeks. In the Zepbound label pool of its two obesity trials, the 15 mg dose was associated with nausea (28%), diarrhea (23%), vomiting (13%), and constipation (11%) vs 8%, 8%, 2%, and 5% on placebo[7]. Treatment discontinuation due to adverse events ran 4.3 to 7.1% on tirzepatide vs 2.6% on placebo. Mean weight change at the 15 mg arm was -20.9% at 72 weeks vs -3.1% on placebo.

Side-by-side: Foundayo’s GI adverse-event rates land in the same broad range as semaglutide and tirzepatide. The published ATTAIN-1 numbers report the GI dominance qualitatively and the discontinuation rate quantitatively (5.3 to 10.3% on orforglipron vs 2.7% on placebo), which is comparable to STEP-1 (7.0% vs 3.1%) and slightly higher at the top end than SURMOUNT-1 (4.3 to 7.1% vs 2.6%). Weight-loss magnitude favors injectable tirzepatide at the highest dose (-20.9% vs -11.2% for Foundayo at 36 mg in the trial, the 17.2 mg tablet), with semaglutide intermediate (-14.9%). The Foundayo value proposition is the oral pill route, not a superior tolerability profile. For a deeper efficacy and pricing comparison see Foundayo vs Wegovy vs Zepbound: side-by-side comparison.

Magnitude comparison

Selected adverse-event rates from pivotal weight-management trials of GLP-1 receptor agonists: Foundayo (FDA label pool of ATTAIN-1 and ATTAIN-2 for nausea; ATTAIN-1, n=3,127, 72 wk, for discontinuations), Wegovy (semaglutide 2.4 mg, STEP-1, n=1,961, 68 wk), and Zepbound (tirzepatide 15 mg; GI rows from the Zepbound label pool of Studies 1 and 2, discontinuation row from SURMOUNT-1, n=2,539, 72 wk). Treatment discontinuations due to adverse events (rightmost rows) are the cleanest cross-trial tolerability metric because they integrate severity and persistence across the full trial duration. Foundayo's discontinuation range overlaps both injectable comparators, supporting the trial-level conclusion that the oral pill produces a broadly class-typical AE profile.[1][5][6][7]

  • Nausea — Wegovy 2.4 mg (STEP-1)44 %
    vs 17.4% placebo
  • Nausea — Zepbound 15 mg (label pool, Studies 1+2)28 %
    vs 8% placebo
  • Nausea — Foundayo 17.2 mg (36 mg in trials; FDA label pool)35 %
    vs 10% placebo; pools ATTAIN-1 and ATTAIN-2
  • Diarrhea — Wegovy 2.4 mg (STEP-1)31 %
    vs 15.9% placebo
  • Diarrhea — Zepbound 15 mg (label pool, Studies 1+2)23 %
    vs 8% placebo
  • Constipation — Wegovy 2.4 mg (STEP-1)23 %
    vs 9.5% placebo
  • Constipation — Zepbound 15 mg (label pool, Studies 1+2)11 %
    vs 5% placebo
  • Vomiting — Wegovy 2.4 mg (STEP-1)24 %
    vs 6.5% placebo
  • Vomiting — Zepbound 15 mg (label pool, Studies 1+2)13 %
    vs 2% placebo
  • AE discontinuation — Foundayo 6-36 mg range (ATTAIN-1)10 %
    5.3-10.3% dose-dependent vs 2.7% placebo
  • AE discontinuation — Wegovy 2.4 mg (STEP-1)7 %
    vs 3.1% placebo
  • AE discontinuation — Zepbound 5-15 mg range (SURMOUNT-1)7 %
    4.3-7.1% dose-dependent vs 2.6% placebo
Selected adverse-event rates from pivotal weight-management trials of GLP-1 receptor agonists: Foundayo (FDA label pool of ATTAIN-1 and ATTAIN-2 for nausea; ATTAIN-1, n=3,127, 72 wk, for discontinuations), Wegovy (semaglutide 2.4 mg, STEP-1, n=1,961, 68 wk), and Zepbound (tirzepatide 15 mg; GI rows from the Zepbound label pool of Studies 1 and 2, discontinuation row from SURMOUNT-1, n=2,539, 72 wk). Treatment discontinuations due to adverse events (rightmost rows) are the cleanest cross-trial tolerability metric because they integrate severity and persistence across the full trial duration. Foundayo's discontinuation range overlaps both injectable comparators, supporting the trial-level conclusion that the oral pill produces a broadly class-typical AE profile.

Hypoglycemia risk: narrow in obesity-only, broader in T2D combination

Hypoglycemia is a labeled risk for every GLP-1 receptor agonist, but the clinical relevance is highly population- dependent. In ATTAIN-1 (adults with obesity without type 2 diabetes), clinically significant hypoglycemia was not a prominent adverse-event category — the trial population did not have the failed glucose counter- regulation that defines diabetes, and orforglipron, like other GLP-1 RAs, augments insulin secretion only in response to elevated glucose[1]. In monotherapy for weight management in adults without diabetes, hypoglycemia is uncommon but not absent: the label reports glucose below 54 mg/dL in 0.6% of Foundayo-treated patients in that trial vs none on placebo, with no severe episodes[4].

In ATTAIN-2 (adults with obesity and type 2 diabetes), the picture shifts. Many of these patients were also on background diabetes therapy, including in some cases insulin or sulfonylureas. The Foundayo label specifically warns: hypoglycemia risk is increased when used with insulin or insulin secretagogues such as sulfonylureas[4]. The clinical guidance most prescribers follow is to reduce the insulin or sulfonylurea dose at Foundayo initiation, monitor blood glucose closely during titration, and adjust the secretagogue or insulin dose downward as weight loss and glycemic improvement progress.

The takeaway: for the typical Foundayo weight-management candidate (adult with obesity, no diabetes), hypoglycemia is uncommon (glucose below 54 mg/dL in 0.6% of patients in the trial without diabetes), though the label still lists it as a possible effect. For the subset of patients who also have T2D and are on insulin or a sulfonylurea, the risk is real, labeled, and managed through coordinated secretagogue or insulin dose reduction. For broader context on the orforglipron mechanism see What is orforglipron (Foundayo)?

Black box warning and contraindications

The Foundayo FDA label carries the standard GLP-1 class boxed warning for thyroid C-cell tumors, derived from rodent carcinogenicity studies in which GLP-1 receptor agonists produced thyroid C-cell tumors at clinically relevant exposures[4]. Human relevance is unclear; postmarket surveillance across multiple GLP-1 RAs has not demonstrated a clear medullary thyroid carcinoma signal. The boxed warning nevertheless instructs:

  • Do not use Foundayo in patients with a personal or family history of medullary thyroid carcinoma.
  • Do not use Foundayo in patients with Multiple Endocrine Neoplasia syndrome type 2.
  • Counsel patients on the potential risk and the symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).

The only other contraindication is serious hypersensitivity to orforglipron or any product component. Pregnancy is not on that list — it sits in the warnings instead (SetID 8ac446c5-feba-474f-a103-23facb9b5c62), reflecting the absence of adequate human data and the plain clinical reasoning that weight loss is not a treatment goal during pregnancy. The label directs stopping Foundayo as soon as a pregnancy is recognized. Patients of childbearing potential should use effective contraception; no pre-conception window appears on this label, so discuss timing with the prescriber[4].

Patients who experience symptoms suggestive of any boxed- warning or labeled-warning event — persistent neck mass or hoarseness, severe persistent abdominal pain, right-upper- quadrant pain with fever or jaundice, severe persistent vomiting or diarrhea producing dehydration, recurrent severe hypoglycemia (in the T2D-plus-secretagogue subgroup), or signs of an allergic reaction — should contact the prescribing clinician promptly, and Foundayo should generally be discontinued pending evaluation.

What patients should know going in

Five practical takeaways for a patient evaluating Foundayo:

  1. Expect GI side effects, especially in the first 2 to 4 weeks of each dose step. Nausea, mild diarrhea or constipation, and occasional vomiting are the most common. They are usually mild to moderate. The label reports that nausea, vomiting, and diarrhea were more common during dose escalation and decreased over time. The label moves patients up to 5.5 mg, then allows increases to 9, 14.5, or 17.2 mg based on response and tolerability, with a maximum of 17.2 mg daily; 36 mg is a trial dose, not a tablet you can buy.
  2. Take Foundayo once a day, with or without food, and swallow the tablet whole. There is no water rule or 30-minute wait. Consistency matters most: if you miss a dose, take it as soon as possible without doubling the next one; if you miss 7 or more doses in a row, the label says to restart escalation at a lower dose, so check with your clinician.
  3. If you have type 2 diabetes and are on insulin or a sulfonylurea, talk to your prescriber about secretagogue or insulin dose adjustment. This is the highest-yield safety conversation specific to the T2D population. Hypoglycemia risk is managed primarily by downward-titrating the background diabetes therapy.
  4. Call your prescriber for red-flag symptoms. Severe persistent abdominal pain (possible pancreatitis), right-upper-quadrant pain with fever or jaundice (possible gallbladder), persistent neck mass or unexplained persistent hoarseness (boxed thyroid warning), signs of an allergic reaction, persistent severe vomiting or diarrhea (dehydration and renal-injury risk), or recurrent severe hypoglycemia in the T2D + secretagogue subgroup. Do not wait.
  5. Know that weight regain after stopping is the expected pattern for every GLP-1, not a Foundayo-specific failing. ATTAIN-MAINTAIN[3] documented that maintenance requires continued therapy — the placebo arm regained a substantial fraction of prior loss within 52 weeks. If you plan to stop, plan the off-ramp with your clinician.

Bottom line

The three pivotal ATTAIN trials — ATTAIN-1 in adults with obesity without diabetes[1], ATTAIN-2 in adults with obesity and type 2 diabetes[2], and ATTAIN-MAINTAIN in switch-and-maintain from injectable GLP-1s[3] — converge on the same headline: Foundayo’s adverse-event profile is class-typical for a GLP-1 receptor agonist. Gastrointestinal events dominate, are mostly mild to moderate, are more common at the middle and top doses than at the lowest dose, and concentrate during the titration window. Adverse-event discontinuations across the orforglipron arms run 5 to 10%, broadly comparable to high-dose Wegovy[5] and Zepbound[6].

The two distinctly Foundayo-relevant pieces of the safety picture: the label allows dosing with or without food but asks oral-contraceptive users to switch to a non-oral method or add a barrier method for 30 days after starting and after each dose increase, and hypoglycemia risk is highest in T2D patients also on insulin or a sulfonylurea (with the standard mitigation: reduce the background secretagogue or insulin dose at initiation). The boxed thyroid C-cell tumor warning and the standard pancreatic, gallbladder, renal, allergic, and pregnancy warnings apply identically to Foundayo as they do to the rest of the GLP-1 class[4].

For Foundayo dosing and titration logistics, see the week-by-week titration guide. For tolerability comparisons within the GLP-1 class, see the Foundayo vs Wegovy vs Zepbound comparison. For the broader oral-pill landscape including Rybelsus, see GLP-1 oral pills compared. For an interactive view of when GLP-1 side effects emerge across the titration ladder, see the GLP-1 side-effect timeline tool.

Further reading

References

  1. 1.Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, Zhou C, Macpherson L, Allen SE, Ahmad NN, Klise SR; ATTAIN-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025. PMID: 40960239.
  2. 2.Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG, Aberle J, Bain SC, Allen S, Sarker E, Wu Q, Stefanski A, Jouravskaya I; ATTAIN-2 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026. PMID: 41275875.
  3. 3.Aronne LJ, Horn DB, le Roux CW, Chao AM, Ho W, Halpern B, Griffin R, Xie C, Valderas EG, Lee CJ, Ribeiro A, Hyman DM, Glass L, Xavier N. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026. PMID: 42120723.
  4. 4.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, for oral use — US Prescribing Information. Includes boxed warning for thyroid C-cell tumors, sections 5.1-5.10 warnings and precautions, and section 6.1 adverse reactions. DailyMed (FDA Approved Labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  5. 5.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
  6. 6.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  7. 7.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, for subcutaneous use — US Prescribing Information. DailyMed (FDA Approved Labeling). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  8. 8.Ma X, Li YG, Raha S, Sperry DC, Coutant DE, Bhattachar S. Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight. Diabetes Obes Metab. 2026. PMID: 41994902.

Orforglipron (Foundayo) Side Effects: Label Trial Rates

What the FDA Foundayo label and the ATTAIN-1 phase 3 trial actually report for orforglipron side effects — the GI rates, the boxed MTC warning, the pancreatitis and gallbladder signal, and how the oral pill compares to injectable Wegovy and Zepbound.

11 min read

Retatrutide vs Foundayo (orforglipron) — TRIUMPH-1 vs ATTAIN-1 cross-trial evidence

Retatrutide −25.0% TBWL at 12 mg / 80 wk (TRIUMPH-1, NEJM 2026) vs Foundayo (orforglipron) ~−11% at 17.2 mg / 72 wk (ATTAIN-1), roughly 2.2× on a cross-trial basis. Both are Eli Lilly molecules; Foundayo is FDA-approved (April 2026), retatrutide is investigational.

12 min read

Retatrutide Side Effects: Comprehensive Phase 3 Evidence Review

TRIUMPH-1 pivotal phase 3 retatrutide adverse-event review: GI rates, a dysesthesia signal (12.5% vs 0.9% placebo) also seen with high-dose semaglutide, 11.3% discontinuation, and head-to-head AE comparison with Wegovy, Zepbound, and Foundayo.

15 min read

GLP-1 Trial Results Q3 2026: Retatrutide TRIUMPH, Survodutide & Orforglipron ACHIEVE-4

Quarterly digest of GLP-1 and incretin trial results through mid-October 2026: retatrutide TRIUMPH-1 and TRIUMPH-2, survodutide SYNCHRONIZE, orforglipron ACHIEVE-4, Mounjaro's new cardiovascular indication, CagriSema under FDA review, and what comes next.

14 min read

Foundayo vs Wegovy: Head-to-Head Evidence Comparison

Foundayo (orforglipron) is an oral small-molecule GLP-1 tablet; Wegovy (semaglutide) is a weekly injection or daily tablet. ATTAIN-1 ~11.1% weight loss vs STEP-1 ~14.9% and OASIS 4 (tablet) ~13.6%. Trial data, side effects, CV evidence, dosing rules, and a decision framework.

14 min read

What Is Orforglipron (Foundayo)? Mechanism, Maker & Pronunciation

Orforglipron (Foundayo) is Eli Lilly's once-daily oral GLP-1, the first non-peptide GLP-1 approved for weight loss, cleared by the FDA on April 1, 2026. Being a small molecule is why it can be a pill. How it works, ATTAIN-1 results, and how to pronounce it.

10 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

From $200/mo

starting dose

Get started →
7.8

SnagRx

Compounded semaglutide and tirzepatide at a flat lifetime price

Read full review →

From $99/mo

Get started →
7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

From $139/mo

4-month plan rate

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →